Catherine Lucas

Dr. Lucas has more than 30 years of experience in science and in the biotechnology industry, leading research and development teams in the early development of novel biomolecules from research through IND approval and first-in-human testing. She has worked in a number of healthcare industries in diagnostics, biotechnology and drug delivery, and has led multiple national and international teams, in small start-up companies and large pharmaceutical companies. Dr. Lucas was Vice President of Technical Development at IGM Biosciences for 4 years and worked at ALZA and Johnson and Johnson as Vice President of Technical Development for 10 years, developing long-term implants for the delivery of biomolecules as well as non-invasive technologies for the delivery of biomolecules to the central nervous system. Previously, Dr. Lucas worked at Cell Genesys on chimeric antigen receptors and on fully human antibodies derived from the XenoMouse. She worked at Genentech Inc. from 1985 to 1993, notably as part of project teams responsible for developing Fc fusion proteins, and a candidate HIV vaccine project. Dr. Lucas holds a B.A. in Biochemistry and a Ph.D. in Neurochemistry from the University of Sciences in Paris, France. She completed her post-doctoral studies in neurochemistry at Stanford University.